Biopharmaceuticals
'Big pharma' is weaving biotech into its research regime, developing multiple therapeutic indications for protein drugs
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
May 10, 2004 Cover
Volume 82, Issue 19
'Big pharma' is weaving biotech into its research regime, developing multiple therapeutic indications for protein drugs
Credit:
'Big pharma' is weaving biotech into its research regime, developing multiple therapeutic indications for protein drugs
Presidential directive, ‘hot’ labs to prepare U.S. for bioterrorism
Chemists gather to paint a 21st-century picture of the resurgent field of main-group chemistry
Corning's chief technology officer chose new challenges over retirement to academia
U.S., EU share views on regulation at trans-Atlantic conference on chemicals
Frailty, erectile dysfunction, scarring, and thrombosis/atherosclerosis drugs introduced